ENTA News and Press, Enanta Pharmaceuticals Inc. From 02/10/22

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at t...

Image source: The Motley Fool. Enanta Pharmaceuticals (NASDAQ: ENTA) Q1 2022 Earnings Call Feb 08, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Enanta Pharmaceuticals (ENTA) Q1 2022 Earnings Call Transcript

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2022 Earnings Conference Call February 08, 2022, 04:30 PM ET Company Participants Jennifer Viera - IR Jay Luly - President and CEO Paul Mellett - CFO Nathalie Adda - Chief Medical Officer Conference Call Participants Brian Abrahams - RBC Capital Markets ...

Enanta Pharma press release (NASDAQ:ENTA): Q1 GAAP EPS of -$1.48 misses by $0.37. Revenue of $27.65M (-12.9% Y/Y) beats by $0.28M. For further details see: Enanta Pharma GAAP EPS of -$1.48 misses by $0.37, revenue of $27.65M beats by $0.28M

Expects to Begin Dosing in a First-in-Human Study of EDP-235, an Oral 3CL Protease Inhibitor Specifically Designed for the Treatment of COVID-19, This Month Completed Enrollment in RSVP, a Phase 2b Study of EDP-938 in Adults With Community-Acquired Respiratory Syncytial Viru...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2021 afte...

Plans to Initiate First-in-Human Study of EDP-235, an Oral 3CL Protease Inhibitor Specifically Designed for the Treatment of COVID-19, in February 2022 Completes Enrollment for RSVP, a Phase 2 Study of EDP-938 in Community-Acquired Respiratory Syncytial Virus (RSV) Infec...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 40 th Annual J.P...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips While this isn’t the end of giant pharmaceutical companies, there is a new generation of biotechs that have been able to advance rapidly due to the massive advances in computer technology in recent decades. These A-r...

The following slide deck was published by Enanta Pharmaceuticals, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Enanta Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation